OptimizeRx Corporation (OPRX) Dividend History

Company News

• OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations

  OptimizeRx Corp. has received a purported notice of nominations from a stockholder, Whetstone Capital Advisors, LLC, regarding its intention to nominate two candidates for election to the OptimizeRx Board of Directors at the Company's 2025 Annual Meeting of Stockholders.

  GlobeNewswire Inc.
• Smith Micro Software, Inc. (SMSI) Reports Q2 Loss, Misses Revenue Estimates

  Smith Micro Software, Inc. reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a loss of $0.35. The company's revenue of $5.14 million also missed estimates. The stock has lost about 62.9% since the beginning of the year.

  Zacks Investment Research

  Featured Companies: SMSI
• New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations

  • 84% of Patients Arrive at Doctor Visits Underinformed• Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies• OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client

  GlobeNewswire Inc.
• Expert Ratings For OptimizeRx

  OptimizeRx (NASDAQ:OPRX) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.6, with a high estimate of $17.00 and a low estimate of $13.00. This current average has increased by 12.31% from the previous average price target of $13.00. Breaking Down Analyst Ratings: A Detailed Examination The analysis of recent analyst actions sheds light on the perception of OptimizeRx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Grossman Stifel Maintains Buy $13.00 $13.00 Constantine Davides JMP Securities Maintains Market Outperform $15.00 - Constantine Davides JMP Securities Announces Market Outperform $15.00 - David Grossman Stifel Maintains Buy $13.00 $13.00 Sean Dodge RBC Capital Maintains Outperform $17.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', ...Full story available on Benzinga.com

  Benzinga
• OptimizeRx Reports First Quarter 2024 Financial Results

  WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period.

  GlobeNewswire Inc.